Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | PYGB | P11216 | 2/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
| ▸ | FNTA | P49354 | 1/20 | 0.40 |
| ▸ | FNTB | P49356 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | RRM1 | P23921 | 1/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.37 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.37 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20161657 | 1.00 | EPHX2 (0.42) | EPHX2MAPK1PYGBMMP8FNTA | |
| SCHEMBL20161921 | 1.00 | EPHX2 (0.42) | EPHX2MAPK1PYGBMMP8FNTA | |
| SCHEMBL20161562 | 1.00 | EPHX2 (0.42) | EPHX2MAPK1PYGBMMP8FNTA | |
| SCHEMBL20161322 | 1.00 | EPHX2 (0.42) | EPHX2MAPK1PYGBMMP8FNTA | |
| SCHEMBL20161932 | 1.00 | EPHX2 (0.42) | EPHX2MAPK1PYGBMMP8FNTA | |
| SCHEMBL20161290 | 0.89 | PYGB (0.43) | MAPK1PYGBGAA | |
| SCHEMBL20161302 | 0.89 | PYGB (0.43) | MAPK1PYGBGAA | |
| SCHEMBL20161920 | 0.89 | PYGB (0.43) | MAPK1PYGBGAA | |
| SCHEMBL20161927 | 0.88 | GJB2 (0.46) | MAPK1 | |
| SCHEMBL20161635 | 0.88 | GJB2 (0.46) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11045411-B2 | Process for treating keratin materials using amide, acid or ester c-glycoside derivatives, and cosmetic composition containing same | L'OREAL (FR) | 2021-06-29 | — | — | US | disclosed |
| US-20180133137-A1 | PROCESS FOR TREATING KERATIN MATERIALS USING AMIDE, ACID OR ESTER C-GLYCOSIDE DERIVATIVES, AND COSMETIC COMPOSITION CONTAINING SAME | L'OREAL (FR) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133137-A1 | PROCESS FOR TREATING KERATIN MATERIALS USING AMIDE, ACID OR ESTER C-GLYCOSIDE DERIVATIVES, AND COSMETIC COMPOSITION CONTAINING SAME | KRT18, CUTA, GLA | EPHX2 1855/4885MAPK1 2735/4885PYGB 3409/4885 |
| US-11045411-B2 | Process for treating keratin materials using amide, acid or ester c-glycoside derivatives, and cosmetic composition containing same | KRT18, CUTA, GLA | EPHX2 1855/4885MAPK1 2735/4885PYGB 3409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.